Exelixis | Pasivo Circulante



Current Liabilities Cambio Fecha
Acadia Pharmaceuticals USD 302.53M 92.34M 2025-03
Agios Pharmaceuticals USD 52.37M 28.79M 2025-03
Amgen USD 23.01B 91M 2025-03
AstraZeneca USD 29.13B 1.26B 2025-03
Bayer EUR 28.95B 3.9B 2024-12
BioMarin Pharmaceutical USD 628.21M 21.22M 2025-03
Bristol-Myers Squibb USD 24.07B 296M 2025-03
Cytokinetics USD 159.73M 19.95M 2025-03
Eisai JPY 381.62B 54.78B 2024-12
Eli Lilly USD 30.07B 1.69B 2025-03
Exelixis USD 403.77M 9.42M 2025-01
Genmab DKK 5.31B 723M 2024-12
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.89B 244.96M 2025-03
Ionis Pharmaceuticals USD 250.29M 59.02M 2025-03
MacroGenics USD 55.53M 3.78M 2024-12
Merck USD 25.17B 3.25B 2025-03
Moderna USD 1.6B 602M 2025-03
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 36.45B 6.54B 2025-03
Sanofi 29.16B 865M 2024-12
Takeda JPY 2.1T 289.27B 2024-12
Ultragenyx Pharmaceutical USD 344.15M 59.14M 2024-12
Xencor USD 88.44M 1M 2025-03



Exelixis Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.